A different kind of case study, designed for the busy clinician.
The program offers 3 modules, each with 4 cases involving serious infections that impact immunocompromised or critically ill patients, including cytomegalovirus and multidrug-resistant Gram-negative bacterial infections.
The interactive online case-based format allows you to reflect on your own clinical decision making, and compare your decisions with those of an expert panel.
Complete each module individually for separate credits. Each module offers:
All other health care professionals completing this course will be issued a statement of participation.
Target Audience: This program is intended for specialists in infectious diseases, transplant, hematology/oncology, critical care, hospitalists and hospital pharmacists.
Program Overview: Patients who are immunocompromised or critically ill represent a particularly vulnerable population for infectious disease. One of the most common infections in immunosuppressed patients, including hematopoietic and solid organ transplant recipients, is cytomegalovirus (CMV). Infections caused by Gram-negative bacteria are also a significant concern in immunocompromised or critically ill patients. Management of both CMV and Gram-negative bacterial infections can be complicated by multidrug resistance, which limits treatment options and negatively impacts outcomes. New options for preventing and managing these serious infections have recently been introduced, and other agents are in late stages of clinical development.
This activity has been designed to help clinicians analyze and apply best practices in managing serious infections in immunocompromised and critically ill patients. This interactive online case-based format allows you to reflect on your own clinical decision making, and compare your decisions with those of an expert panel. Each module also provides the opportunity to review key risk factors for infections, issues that may impact therapeutic choices, and recently approved and investigational agents.
Educational approach: The format allows you to reflect on your own reasoning process through a series of different clinical scenarios and compare your approach to that of a selected panel of experts within the transplant and bacterial infectious disease areas of expertise.
This format is modeled on the validated script concordance test, which, similar to a case study, simulates clinical situations in which physician must make decisions about diagnosis, treatment or management.
Modules and cases: To accommodate short bursts of learning and to address a variety of infections, this program offers 3 modules with 4 cases per module:
Each case will take approximately 15 minutes to complete for a total of 1 hour per module.
You may choose to complete one or all modules; you do not have to complete all modules to be eligible for CME/CE credit.
Stop and start: The program is designed to save your progress across multiple sessions, so you can start and stop at any time. As long as you have internet access, you can log in with your phone or computer, whether you’re waiting in the grocery line, in between patients, or during lunch.
Roy F. Chemaly, MD
Professor of Medicine
Director, Infection Control Section
Director of Clinical Virology
Department of ID/IC/EH
UT MD Anderson Cancer Center
Keith Kaye, MD
Professor of Internal Medicine
Director of Clinical Research, Division of Infectious Diseases
University of Michigan Medical School
Camille Kotton, MD
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
From the Chair of the Scientific Committee
Upon completion of the overall program, you should be able to
Each module has specific learning objectives. Select a module to learn more.
Jointly provided by Context Healthcare Group and the University of Cincinnati with ACPE accreditation provided by the University of South Carolina College of Pharmacy.
This activity is supported by an independent education grant from Merck & Co., Inc.